PSMAI cut-off value for mortality in men: 680.1 mm2/m2
Por um escritor misterioso
Descrição
ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer
Reduced Acquisition Time per Bed Position for PET/MRI Using 68Ga-RM2 or 68Ga-PSMA-11 in Patients With Prostate Cancer: A Retrospective Analysis
The unenhanced CT image of a 73-year-old male patient (A) at the L3
Computed tomographic images at the the middle third lumbar vertebral
Kaplan-Meier survival curves of prostate cancer patients treated with
Safety and Efficacy of [177Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years
PSMAI cut-off value for mortality in men: 680.1 mm2/m2
Cemalettin AYDIN, Inonu University, Malatya, Faculty of Medicine
Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177- PSMA-617 radioligand therapy, BMC Urology
Frontiers Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China
PSMAI cut-off value for mortality in men: 680.1 mm2/m2
EAU 2023: LuTectomy: A Prospective Study of Dosimetry, Safety and Potential Benefit of Upfront 177Lu-PSMA-617 Radioligand Therapy Prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer
Cancers, Free Full-Text
de
por adulto (o preço varia de acordo com o tamanho do grupo)
.png)